ARDX stock forecast
Our latest prediction for Ardelyx, Inc.'s stock price was made on the June 4, 2019 when the stock price was at 2.70$.
In the short term (2weeks), ARDX's stock price should outperform the market by 1.20%. During that period the price should oscillate between -8.47% and +14.28%.
In the medium term (3months), ARDX's stock price should outperform the market by 6.79%. During that period the price should oscillate between -19.52% and +42.00%.Get email alerts
About Ardelyx, Inc.
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -1.65$ per share.
The book value per share is 2.63$
Three months stock forecastJune 4, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|